Tools
Stock profile

STANDARD BIOTOOLS INC. (LAB)

LAB · Latest close $0.57 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$0.57
As of Nov 18, 2026
Tracked funds holding
1 of 149
2026 Q2 13F filings
Opened / added
0 / 0
vs previous quarter
Trimmed / exited
1
vs previous quarter

STANDARD BIOTOOLS INC. (LAB) is held by 1 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($46.9K bought vs $0 sold). Latest close $0.57 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 5, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $46.9K
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Viking Global Investors — 1 tracked fund hold LAB. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $46.9K) vs 0 sales ($0). Latest buy: Nov 5, 2026. Insider trading

Often held alongside

Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Viking Global Investors0.14%58,651,170HELD Q3 filed Nov 16
Slate Path Capital——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -38.0% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

2.210.472024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding142 of 8,857 filers
Long-only filers among them142
Change vs 2026 Q1-7 net · 139 entered · 146 exited
Shares reported, all filers295,769,374
Reported value, all filers$242.2M

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryPharmaceutical Preparations (SIC 2834)
Revenue · FY2025$85.3M
Net income · FY2025$-74.9M
Total assets · FY2025$567.8M
Shares outstanding392,578,808
Market cap (at latest close)$223.8M

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 3, 2026.

Short interest

Shares short · Oct 15, 20262,445,793
Share of shares outstanding0.62%
Days to cover2.50

Shares short at recent settlements — Jul 31, 2026: 2.7M · Aug 14, 2026: 2.4M · Aug 31, 2026: 3.0M · Sep 15, 2026: 2.6M · Sep 30, 2026: 2.5M · Oct 15, 2026: 2.4M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 3, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 320 · Aug 14, 2026: 0 · Aug 31, 2026: 8K · Sep 15, 2026: 11 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 3, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $46.9K), against 0 sales by 0 insiders ($0). Latest buy: Nov 5, 2026.

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Carey Thomas D. · 75,000 shares on Nov 5, 2026 · filed Nov 5, 2026$0.63-15.7% (close Nov 6, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 6, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 5, 2026Carey Thomas D.Buy75,000$0.63$46.9KSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
May 23, 2025Mackay SeanOfficer13,217$12.4KMay 23, 2025SEC filing
May 23, 2025Kim Hanjoon AlexOfficer1,428$1.3KMay 23, 2025SEC filing
May 23, 2025Egholm MichaelOfficer, Director5,473$5.2KMay 23, 2025SEC filing
May 22, 2025Egholm MichaelOfficer, Director5,116$5.1KMay 22, 2025SEC filing
May 22, 2025Mackay SeanOfficer12,536$12.6KMay 22, 2025SEC filing
May 22, 2025Kim Hanjoon AlexOfficer1,355$1.4KMay 22, 2025SEC filing
May 21, 2025Kim Hanjoon AlexOfficer1,407$1.5KMay 21, 2025SEC filing
May 21, 2025Mackay SeanOfficer12,838$13.2KMay 21, 2025SEC filing
May 21, 2025Egholm MichaelOfficer, Director4,719$4.9KMay 21, 2025SEC filing
Nov 12, 2024Black Jeffrey G.Former Officer57,971$123.1KNov 12, 2024SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jun 12, 2026SCHEDULE 13D-36.5% (close Jun 15, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jun 15, 2026). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026MAK CAPITAL ONE LLCSC 13G/A28,813,9047.3%Jun 30, 2026SEC filing
Aug 14, 2026LONG FOCUS CAPITAL MANAGEMENT, LLCSC 13G23,500,0006.0%Jun 30, 2026SEC filing
Jul 30, 2026BlackRock, Inc.SC 13G/A7,911,3472.0%Jun 30, 2026SEC filing
Jun 12, 2026VIKING GLOBAL INVESTORS LPSC 13D58,651,17015.0%Jun 6, 2026SEC filing
Jun 9, 2026Casdin Capital, LLCSC 13D/A88,783,85622.7%Jun 6, 2026SEC filing
May 15, 2026MAK Capital Fund LPSC 13G/A26,172,6266.7%Mar 31, 2026SEC filing
May 15, 2026VIKING GLOBAL INVESTORS LPSC 13G/A58,651,17015.0%Mar 31, 2026SEC filing
Jan 7, 2026MAK Capital Fund LPSC 13G19,967,5655.2%Dec 31, 2025SEC filing
Nov 28, 2025Casdin Capital, LLCSC 13D/A88,433,85622.9%Nov 25, 2025SEC filing
Mar 4, 2025Casdin Capital, LLCSC 13D/A76,075,63620.4%Feb 28, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Pharmaceutical Preparations (SIC 2834). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Screens & lenses

Insiders

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Financial Screens

· Net-Net (NCAV) — Market cap below net current asset value

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

· Late Filings (NT) — Last 2 years: a late-filing notification (NT form)

Key figures

· Net-Net (NCAV) — NCAV: $310.8M · Market cap: $236.6M · NCAV / market cap: 1.31

· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $46.9K · Latest buy: Nov 5, 2026

· Distress Risk (Altman Z″) — Z″-Score: -1.44 · Working capital / assets: 0.61 · Retained earnings / assets: -2.22 · EBIT / assets: -0.19 · Equity / liabilities: 2.96

· Late Filings (NT) — Latest event: Aug 12, 2025 · Events in 2 yrs: 1 · Latest form: NT 10-Q

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2023 Q2, ranked #33 of 50.

Also held by the tracked funds that hold LAB — ranked by lift, the co-holding pattern described in Methodology: Merck & Co., Inc. (MRK) · ELI LILLY & Co (LLY) · PFIZER INC (PFE) · AbbVie Inc. (ABBV) · BRISTOL MYERS SQUIBB CO (BMY) · ASTRAZENECA PLC (AZN) · ABBOTT LABORATORIES (ABT) · NOVARTIS AG (NVS).

8 of the 8 are same-industry (SIC) fillers: fewer than 4 stocks met the lift rule for this stock.

Recent 8-K filings

FiledItemsSource
Nov 16, 20268.01 Other EventsSEC filing
Nov 3, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Oct 5, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

Merck & Co., Inc. (MRK) · Track Record: how the signals scored · Practice timing on LAB

One email a week: the week’s new filings and research. Subscribe free

← L  ·  LAC →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.